SOX10 Expression in Malignant Melanoma, Carcinoma, and Normal Tissues
The DOI matches its Crossref record; 7 of the 8 references it cites were found in a registry or an index.
Abstract
Sry-related HMg-Box gene 10 (SOX10) is a nuclear transcription factor that plays an important role in melanocytic cell differentiation. It has been shown to be a sensitive marker of melanoma including spindle and desmoplastic subtypes. We assessed its frequency of expression in melanoma, carcinoma, benign nevi, and non-neoplastic tissues with routine immunohistochemistry for SOX10. The 109 primary melanoma included 49 epithelioid, 19 spindle cell, 22 desmoplastic, and 19 mixed spindle cell/desmoplastic melanoma. All primary, except 8 desmoplastic melanoma, and 11 metastatic melanoma were strongly and diffusely nuclear SOX10-positive. Six desmoplastic melanoma had ≤10% cells positive, and 2 were <50% positive, all of 3+ intensity. Eighteen of 149 (12%) breast carcinoma were SOX10-positive. All 24 ovarian, 23 endometrial, 26 lung, and 25 colon carcinoma were SOX10-negative. All 43 benign nevi, 18 dysplastic nevi, 68 non-neoplastic and benign skins, and all 56 non-neoplastic breast tissue were SOX10-positive. The sensitivity and specificity for SOX10 in the diagnosis of melanoma are 1.0 and 0.93, respectively; the positive and negative predictive values are 0.87 and 1.0, respectively. SOX10 is a sensitive, specific marker for melanoma. As benign nevi also express SOX10, it cannot be used to differentiate between benign and malignant pigmented skin lesions. Only a small number of breast carcinoma (12%), and breast lobules, express SOX10; no carcinoma of the ovary, endometrium, lung, or colon expressed SOX10.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while some NCSC factors, such as SOX10 and YY1, are activated upon melanoma formation and are required for melanoma growth16,19,29,69”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [69]
Citations
Cites
Bowles, J., Schepers, G., & Koopman, P. (2000) · Developmental Biology · doi:10.1006/dbio.2000.9883 · Cited by 966
Sox10: A Pan-Schwannian and Melanocytic Marker
Nonaka, D., Chiriboga, L., & Rubin, B. P. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181658c14 · Cited by 405
Mollaaghababa, R., & Pavan, W. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206442 · Cited by 222
Orchard, G. E. (2000) · The Histochemical Journal · doi:10.1023/a:1004192232357 · Cited by 148
Ultrastructural localization of HMB‐45 binding sites
Schaumburg‐Lever, G., Metzler, G., & KAISERLING, E. (1991) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.1991.tb01380.x · Cited by 73
Matthew D. Perry, M. D., Hf, S., & Johnston, W. W. (1986) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/77.5.1013 · Cited by 45
Friedman, H. D., & Tatum, A. H. (1991) · PubMed · Cited by 29
Cited by
Miettinen, M., McCue, P. A., Sarlomo-Rikala, M., Biernat, W., Czapiewski, P., Kopczynski, J., Thompson, L. D., Lasota, J., Wang, Z., & Fetsch, J. F. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000398 · Cited by 305
Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST
Prieto-Granada, C. N., Wiesner, T., Messina, J. L., Jungbluth, A. A., Chi, P., & Antonescu, C. R. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000564 · Cited by 294
SOX10: A Useful Marker for Identifying Metastatic Melanoma in Sentinel Lymph Nodes
Willis, B. C., Johnson, G., Wang, J., & Cohen, C. (2014) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000097 · Cited by 99
Self-citationSOX10 Promotes Melanoma Cell Invasion by Regulating Melanoma Inhibitory Activity
Graf, S. A., Busch, C., Bosserhoff, A., Besch, R., & Berking, C. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.128 · Cited by 101
“SOX10 has been established as a sensitive marker for melanocytic lesions, with positive staining in nevi and melanoma (Nonaka et al., 2008; Mohamed et al., 2012).”
BackgroundTRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma
Yoon, E. C., Wang, G., Parkinson, B., Huo, L., Peng, Y. S., Wang, J., Salisbury, T., Wu, Y., Chen, H., Albarracin, C. T., et al. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.04.006 · Cited by 96
Self-citationMelanoma antigens and related immunological markers
Pitcovski, J., Shahar, E., Aizenshtein, E., & Gorodetsky, R. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.05.001 · Cited by 94
“SOX10 is expressed in some normal cell types as well as in some other tumors [221,222].”
BackgroundNasal Cavity and Paranasal Sinuses
Cardesa, A., Alós, L., Nadal, A., & Franchi, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-49672-5_2 · Cited by 88
A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma
Weissinger, S. E., Keil, P., Silvers, D. N., Klaus, B. M., Mӧller, P., Horst, B. A. J., & Lennerz, J. K. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.162 · Cited by 86
UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling
Dikshit, A., Jin, Y. J., Degan, S., Hwang, J., Foster, M. W., Li, C., & Zhang, J. Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1040 · Cited by 80
Plaza, J. A., Bonneau, P., Prieto, V. G., Sangüeza, M., Mackinnon, A. C., Suster, D. I., Bacchi, C. E., Estrozi, B., Kazakov, D. V., Kacerovská, D., et al. (2015) · Journal of Cutaneous Pathology · doi:10.1111/cup.12654 · Cited by 77
Sun, Q., Lee, W., Mohri, Y., Takeo, M., Lim, C. H., Xu, X., Myung, P., Atit, R. P., Taketo, M. M., Moubarak, R. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12733-1 · Cited by 68
Cytologic features of angiosarcoma: A review of 26 cases diagnosed on FNA
Geller, R. L., HooKim, K., Sullivan, H. C., Stuart, L. N., Edgar, M. A., & Reid, M. D. (2016) · Cancer Cytopathology · doi:10.1002/cncy.21726 · Cited by 71
“The ultimate distinction between these 2 differentials requires immunohistochemistry because melanomas are typically negative for vascular markers and positive for S100, SOX10, melan-A, and human melanoma black 45, whereas angiosarcoma shows opposite results.(36,37) Because of their plasmacytoid morphology, angiosarco…”
BackgroundDiener, J., & Sommer, L. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0351 · Cited by 64
“10 (SOX10), for instance, which regulates the melanocytic and glial murine lineages derived from the NC,(39,40) was found highly expressed in melanocytic nevi and malignant melanoma.(24,68,69) Upon depletion”
BackgroundLinks between S chwann cells and melanocytes in development and disease
Raamsdonk, C. D. V., & Deo, M. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12134 · Cited by 60
“They are usually positive for S100 and Sox10, which label both melanocytes and Schwann cells (Mohamed et al., 2013; Palla et al., 2013).”
BackgroundTacha, D., Qi, W., Ra, S., Bremer, R. E., Yu, C., Chu, J., Hoang, L. L., & Robbins, B. A. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0077-oa · Cited by 58
Martins-Filho, S. N., & Putra, J. (2020) · Hepatic Oncology · doi:10.2217/hep-2020-0002 · Cited by 58
Immunohistochemistry in Dermatopathology
Ferringer, T. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0075-ra · Cited by 57
Hernandez, S. D., Rojas, F. R., Laberiano-Fernández, C., Lazcano, R., Wistuba, I. I., & Parra, E. R. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.667067 · Cited by 58
“, 2016), SOX10/S100 as a melanoma marker (Mohamed et al., 2013), and vimentin as a marker for some sarcomas (Figure 1).”
BackgroundEmerging Role of SOX Proteins in Breast Cancer Development and Maintenance
Mehta, G., Khanna, P., & Gatza, M. L. (2019) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-019-09430-6 · Cited by 58
Utility of Sox10 labeling in metastatic breast carcinomas
Nelson, E. R., Sharma, R. B., Argani, P., & Cimino‐Mathews, A. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.08.011 · Cited by 47
Rooper, L. M., McCuiston, A. M., Westra, W. H., & Bishop, J. A. (2018) · Head and Neck Pathology · doi:10.1007/s12105-018-0990-7 · Cited by 45
Jamidi, S. K., Hu, J., Aphivatanasiri, C., Tsang, J. Y., Poon, I. K., Li, J. J. X., Chan, S., Cheung, S., & Tse, G. M.-K. (2020) · Histopathology · doi:10.1111/his.14118 · Cited by 45
“For an internal control, SOX10 expression was found not only in the myoepithelial cells, but also some luminal cells of benign lobules, as previously reported.(19,20,23,37) In conclusion, SOX10 expression in IBCs was highly sensitive for TNBCs, particularly those with a basal-like phenotype.”
ResultInfluentialDesmoplastic Melanoma With Sarcomatoid Dedifferentiation
Kiuru, M. H., McDermott, G. C., Berger, M. F., Halpern, A. C., & BUSAM, K. J. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000201 · Cited by 42
Detection of Occult Invasion in Melanoma In Situ
Bax, M. J., Johnson, T. M., Harms, P. W., Schwartz, J. L., Zhao, L., Fullen, D. R., & Chan, M. P. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.2668 · Cited by 40
Wolf, J., Auw‐Haedrich, C., Schlecht, A., Boneva, S., Mittelviefhaus, H., Lapp, T., Agostini, H. T., Reinhard, T., Schlunck, G., & Lange, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-72864-0 · Cited by 42
Premalignant and malignant lesions of the vagina
Adhikari, P., Vietje, P., & Mount, S. L. (2016) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2016.11.006 · Cited by 35
McGregor, S. M., Alikhan, M. B., John, R. A., Kotler, H. S., Bridge, J. A., Mujacic, I., Kadri, S., Segal, J. P., & Krausz, T. N. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000778 · Cited by 35
Application of Immunohistochemistry in Undifferentiated Neoplasms: A Practical Approach
Kandukuri, S. R., Lin, F., Gui, L., Gong, Y., Fan, F., Chen, L., Cai, G., & Liu, H. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0518-ra · Cited by 35
“60 Spindled fibroblasts and histiocytes, including epithelioid histiocytes as seen in scar tissue, showed weak to no staining with SOX10.”
BackgroundInfluentialDing, Q., Huo, L., Peng, Y. S., Yoon, E. C., Li, Z., & Şahin, A. A. (2022) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2022.04.002 · Cited by 38
Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4
Diener, J., Baggiolini, A., Pernebrink, M., Dalcher, D., Lerra, L., Cheng, P. F., Varum, S., Häusel, J., Stierli, S., Treier, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25326-8 · Cited by 34
SOX‐10 staining in dermal scars
Behrens, E. L., Boothe, W. D., D'Silva, N. C., Walterscheid, B., Watkins, P., & Tarbox, M. B. (2019) · Journal of Cutaneous Pathology · doi:10.1111/cup.13468 · Cited by 33
“2019;46:579–585. wileyonlinelibrary.com/journal/cup 579 Melan A have been used to evaluate residual melanoma in the setting of desmoplastic melanoma (DM) and uveal melanoma.5,7,8 Recent studies have also showed that SOX-10 is a sensitive and specific marker in the evaluation of DM.1,5,7 Differentiating DM from excisio…”
BackgroundMethodInfluentialImmunohistochemistry in the Diagnosis and Classification of Breast Tumors
Sun, H., Ding, Q., & Şahin, A. A. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0464-ra · Cited by 35
Pigmented Lesions of the Nail Unit
Nevares‐Pomales, O. W., Sarriera-Lázaro, C. J., Barrera-Llaurador, J., Santiago-Vázquez, M., Lugo‐Fagundo, N. S., Sánchez, J. E., & Sánchez, J. L. (2018) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001106 · Cited by 31
Yaseen, Z., Gide, T. N., Conway, J. W., Potter, A. J., Quek, C. Y. J., Hong, A., Long, G. V., Scolyer, R. A., & Wilmott, J. S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.810858 · Cited by 31
“SOX10 exhibited a clear nuclear staining pattern with minimal leak into the cytoplasmic region of a cell and served as a useful marker in identifying tumour cells, as reported previously (Mohamed et al., 2013).”
BackgroundAn Update on the Application of Newly Described Immunohistochemical Markers in Soft Tissue Pathology
Lin, G. Y., & Doyle, L. A. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0488-ra · Cited by 30
Combined use of SOX10 and GATA3 in mammary carcinoma
Qazi, M., & McGregor, S. M. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152801 · Cited by 30
Clevenger, J. A., Joseph, C. T., Dawlett, M. A., Guo, M., & Gong, Y. (2014) · Cancer Cytopathology · doi:10.1002/cncy.21458 · Cited by 30
“1%), but not in breast lobular carcinoma, ovarian carcinoma, endometrial carcinoma, lung carcinoma, or colon carcinoma.(27)”
BackgroundMethodInfluentialStowman, A. M., Mills, S. E., & Wick, M. R. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000678 · Cited by 30
Yang, C., Zhang, L., & Sanati, S. (2019) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223419842185 · Cited by 28
“Ki-67 7 (1-20) N/A 6 (1-27) N/A 12 (5-25) N/A”
Immunohistochemistry for Skin Cancers: New Insights into Diagnosis and Treatment of Melanoma
Voiculescu, V. M., Popescu, A.-I., & Costache, M. (2025) · Cancers · doi:10.3390/cancers17111769 · Cited by 29
“In melanocytic lesions, SOX10 is expressed in benign melanocytic nevi [51], primary cutaneous melanomas [19], desmoplastic melanomas [52–54], both pure and mixed desmo-plastic melanomas [55], and melanoma metastases [56].”
Riemenschnitter, C. E., Teleki, I., Tischler, V., Guo, W., & Varga, Z. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-695 · Cited by 27
“In surgical pathology Sox10 - a TF that allows the survival and differentiation of neural crest cells into mature cells - is honored to support the diagnosis of melanoma and nerve sheath tumors (Mohamed et al. 2013; Shin et al. 2012).”
BackgroundYao, W., German, B., Chraa, D., Braud, A., Hugel, C., Meyer, P., Davidson, G., Laurette, P., Mengus, G., Flatter, E., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161438 · Cited by 25
“IHC staining of SOX10, a melanoma transcription factor expressed through early to late stages in this model (23, 24), confirmed that the pigmented cells corresponded to SOX10+ melanoma cells whose number was reduced in ears of Braf/Pten/Tslp–/– mice (Figure 1F; see also Supplemental Figure 3 for cell counting).”
BackgroundSy, A. L., & Hoang, M. P. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-208924 · Cited by 25
Diagnostic error, uncertainty, and overdiagnosis in melanoma
Elder, D. E., Eguchi, M., Barnhill, R. L., Kerr, K. F., Knezevich, S. R., Piepkorn, M. W., Reisch, L. M., & Elmore, J. G. (2022) · Pathology · doi:10.1016/j.pathol.2022.12.345 · Cited by 24
SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue
Chiu, K., Ionescu, D. N., & Hayes, M. M. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02557-1 · Cited by 26
Yin, H., Qin, C., Zhao, Y., Du, Y., Sheng, Z., Wang, Q., Song, Q., Chen, L., Liu, C., & Xu, T. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1641-2 · Cited by 23
DeepSpot: Leveraging Spatial Context for Enhanced Spatial Transcriptomics Prediction from H&E ImagesPreprint
Nonchev, K., Dawo, S., Siliņa, K., Moch, H., Andani, S., Koelzer, V. H., & Rätsch, G. (2025) · medRxiv · doi:10.1101/2025.02.09.25321567 · Cited by 32
“To qualitatively illustrate the predicted spatial transcriptomics, we compare the expression for SOX10 , a known melanoma marker gene [29, 30] for slice MELIPIT-1-2 with available ground truth pathology annotations (Figure 3B, C).”
Vrotsos, E., & Alexis, J. B. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000146 · Cited by 22
Levy, J., Jackson, C. R., Sriharan, A., Christensen, B. C., & Vaickus, L. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.07.897801 · Cited by 22
Izubuchi, Y., Hamada, S., Tanzawa, Y., Fujita, I., Imanishi, J., Koyanagi, H., Shimatani, A., Komatsubara, T., Tanaka, T., Fukushima, M., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05114-1 · Cited by 18
“Because expression of SOX-10 and BRAF V600E were negative in all cases, melanoma could be excluded (Miettinen et al. 2015; Mohamed et al. 2013).”
BackgroundHároníková, L., Zatloukalová, P., Kucerikova, M., Friedlová, N., Tylichová, Z., Kokas, F. Z., Hupp, T. R., Coates, P. J., & Vojtěšek, B. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00637-y · Cited by 18
“SOX10 is an essential transcription factor in neural crest cells, and is highly expressed in melanoma [67], contributing to its tumorous behavior [68].”
BackgroundDiagnostic value of SOX-10 immunohistochemical staining for the detection of uveal melanoma
Alghamdi, S., Zoroquiaín, P., Dias, A. B. T., Alhumaid, S., Aldrees, S. S., & Burnier, M. N. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.566 · Cited by 17
“Although SOX-10 has been proven to be a superior marker for melanoma in skin, benign melanocytic lesions also express SOX-10; therefore, SOX-10 cannot be used to differentiate benign from malignant melanocytic skin lesions [16].”
BackgroundSasaki, K., Hirohashi, Y., Murata, K., Minowa, T., Nakatsugawa, M., Murai, A., Mizue, Y., Kubo, T., Kanaseki, T., Tsukahara, T., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16296 · Cited by 17
SOX11, SOX10 and MITF Gene Interaction: A Possible Diagnostic Tool in Malignant Melanoma
Beleaua, M. A., Jung, I., Braicu, C., Milutin, D., & Gurzu, S. (2021) · Life · doi:10.3390/life11040281 · Cited by 17
“HMB-45, tyrosinase, and SOX10, alongside the Ki67 index, can aid in the distinction between benign and malignant melanocytic tumors [6,10].”
BackgroundResultNagarajan, P., Tetzlaff, M. T., Curry, J. L., & Prieto, V. G. (2016) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2016.05.030 · Cited by 18
DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype
Sanna, A., Phung, B., Mitra, S., Lauss, M., Choi, J., Zhang, T., Njauw, C.-N. J., Cordero, E., Harbst, K., Rosengren, F., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156577 · Cited by 16
“Since both SOX10 and MITF have fundamental roles in developing melanocytes and in melanoma progression (35, 36), depletion of SOX10 in an MITFlo background resulted in high lethality for most of the melanoma cell cultures tested.”
BackgroundSox10 expression in ovarian epithelial tumors is associated with poor overall survival
Kwon, A., Heo, I., Lee, H. J., Kim, G., Kang, H., Heo, J. H., Kim, T. H., & An, H. J. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1918-9 · Cited by 17
Yoon, E. C., Wilson, P. C., Zuo, T., Pinto, M. M., Cole, K. S., & Harigopal, M. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.06.004 · Cited by 18
Almási, S., Kuthi, L., Sejben, A., Vörös, A., Nagy, Á., Zombori, T., & Cserni, G. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03535-4 · Cited by 15
Elgash, M., Young, J. N., White, K., Leitenberger, J. J., & Bar, A. (2023) · Dermatologic Surgery · doi:10.1097/dss.0000000000003945 · Cited by 14
Contemporary diagnostics: Sarcoma pathology update
Brooks, J. S., & Lee, S. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.23853 · Cited by 13
“that may be deceptive by histology alone [89,90].”
BackgroundSejben, A., Vörös, A., Golan, A., Zombori, T., & Cserni, G. (2021) · Pathobiology · doi:10.1159/000512006 · Cited by 13
Nielsen, P. S., Georgsen, J. B., Vinding, M. S., Østergaard, L. R., & Steiniche, T. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192114327 · Cited by 13
“, all primary melanomas (n = 109) and melanoma metastases to the brain (n = 11) were SOX10 positive (with >50% of cells being positive), and all lesions achieved a high SOX10 intensity score by microscopy [32].”
BackgroundSOX10 Knockdown Inhibits Melanoma Cell Proliferation via Notch Signaling Pathway
Tang, Y., & Cao, Y. (2021) · Cancer Management and Research · doi:10.2147/cmar.s329331 · Cited by 13
Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer
Kriegsmann, M., Kriegsmann, K., Harms, A., Longuespée, R., Zgorzelski, C., Leichsenring, J., Muley, T., Winter, H., Kazdal, D. N., Goeppert, B. F., et al. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0751-7 · Cited by 13
Malignant melanoma with metaplastic cartilaginous transdifferentiation: A case report
Berro, J., Halim, N. A., Khaled, C. S., & Assi, H. I. (2019) · Journal of Cutaneous Pathology · doi:10.1111/cup.13539 · Cited by 12
Yu, L., Fan, P., Dong, X., Chen, Y., Sun, D., Jiang, S., & Deng, C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564740 · Cited by 14
Jackson, C. R., Minca, E. C., Kapil, J. P., Smith, S. C., & Billings, S. D. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12834 · Cited by 11
Merkel cell carcinoma, melanoma, metastatic mimics of breast cancer
Troxell, M. L. (2017) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2017.05.009 · Cited by 11
Utility of Sry‐Related HMG‐Box Gene 10 (SOX10) as a marker of melanoma in effusion cytology
Dermawan, J. K. T. K., Underwood, D. L., & Policarpio‐Nicolas, M. L. (2019) · Diagnostic Cytopathology · doi:10.1002/dc.24162 · Cited by 11
Jasim, S. A., Farhan, S. H., Ahmad, I., Hjazi, A. M., Kumar, A., Jawad, M. A., Pramanik, A., Altalbawy, F. M. A., Alsaadi, S. B., & Abosaoda, M. K. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01517-6 · Cited by 10
“The correlations between SOX10 and NES mRNA expression revealed by data mining analyses highlight the role of SOX10 in regulating the properties of cancer stem cells via the up-regulation of Nes-tin (Feng et al. 2017; Mohamed et al. 2013).”
Kim, J. C., Choi, J. W., & Kim, Y. C. (2023) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000002555 · Cited by 10
“The PRAME expression levels and Ki-67 proliferative indices were higher in malignant melanomas than in benign nevi specimens, as previously re-ported, 9,10,17 and the frequent loss of p16 expression was also noted in malignant melanomas, 18 which was con-fi rmed in our results using ALM.”
ResultElder, D. E. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.12.002 · Cited by 10
Immunohistochemistry for the Diagnosis of Melanocytic Proliferations
Jungbluth, A. A., & BUSAM, K. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37457-6.00029-8 · Cited by 11
Loss of prdm1a accelerates melanoma onset and progression
Iwanaga, R., Truong, B. T., Hsu, J. Y., Lambert, K. A., Vyas, R., Orlicky, D. J., Shellman, Y. G., Tan, A. C., Ceol, C. J., & Artinger, K. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23236 · Cited by 11
Use of cytological samples of metastatic melanoma for ancillary studies
Ko, H. M., Saieg, M. A., Santos, G. D. C., Kamel‐Reid, S., Boerner, S. L., & Geddie, W. R. (2017) · Cytopathology · doi:10.1111/cyt.12419 · Cited by 9
Siarov, J., Neittaanmäki, N., Mölne, J., Gillstedt, M., & Paoli, J. (2020) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001749 · Cited by 9
Tinca, A. C., Moraru, R., Cocuz, I. G., Șincu, M. C., Niculescu, R., Sabău, A.-H., Chiorean, D. M., Cozac-Szőke, A. R., Morariu, S.-H., & Cotoi, O. S. (2022) · Biomedicines · doi:10.3390/biomedicines10102500 · Cited by 8
Laparoscopic pancreaticoduodenectomy for metastatic pancreatic melanoma: A case report
Liu, X., Feng, F., Wang, T., Qin, J., Yin, X., Meng, G., Yan, C., Xing, Z., Duan, J., Liu, C., et al. (2018) · Medicine · doi:10.1097/md.0000000000012940 · Cited by 8
Kei, S., & Adeyi, O. A. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0226-ra · Cited by 8
The detectability of intraepidermal melanocytes—A narrative review of immunohistochemical studies
Kuźbicki, Ł., & Brożyna, A. A. (2022) · Journal of Cutaneous Pathology · doi:10.1111/cup.14295 · Cited by 8
Weissinger, S. E., Frick, M., Möller, P., Horst, B. A. J., & Lennerz, J. K. (2016) · International Journal of Surgical Pathology · doi:10.1177/1066896916680072 · Cited by 8
“16 Total 31 9 25 12 10 22 7 28 Head and neck 15 (48) 8 (89) 10 (40) 12 (100) 6 (60) 14 (64) 2 (29) 19 (68) Trunk 9 (31) 1 (11) 8 (32) 0 (0) 1 (10) 6 (27) 3 (43) 5 (18) Limbs 7 (23) 0 (0) 7 (28) 0 (0) 3 (30) 2 (9) 2 (29) 4 (14) Pigm, n (%) .”
Challenges in sentinel node pathology in the era of adjuvant treatment
Franke, V., Madu, M. F., Bierman, C., Klop, W. M. C., van Houdt, W. J., Wouters, M. W. J. M., van de Wiel, B. A., & van Akkooi, A. C. J. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26095 · Cited by 8
“Additional staining for SOX10 (Figure 7) will discriminate between melanoma cells (metastatic melanoma is more than 95% positive) and macrophages (negative).(27,28) Both discordant cases showed pigmented cells with coarse melanin granules consistent with macrophages.”
BackgroundSox10-Positive Cells Within Scars: A Potential Diagnostic Pitfall
Harvey, N. T., Acott, N., & Wood, B. A. (2016) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000756 · Cited by 8
Intramedullary melanotic schwannoma: a rare presentation of a rare tumor. Illustrative case
McCann, M. M., & Hain, J. D. (2023) · Journal of Neurosurgery Case Lessons · doi:10.3171/case22391 · Cited by 7
Soft tissue tumor pathology: New diagnostic immunohistochemical markers
Doyle, L. A. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.012 · Cited by 7
Yim, S., Kim, D., Hong, D., Jung, K. E., Lee, Y., Seo, Y., & Park, S. (2022) · Journal of Cutaneous Pathology · doi:10.1111/cup.14272 · Cited by 7
Digital quantification of PRAME for distinguishing melanoma from nevi compared to manual assessment
Enevoldsen, J., Brogård, M. B., Lade‐Keller, J., Christensen, K. B., Georgsen, J. B., Nielsen, P. S., & Steiniche, T. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155543 · Cited by 7
King, E. M., Cook, M. R., Wittorff, H., Dirksen, W. P., Kisseberth, W. C., & Jennings, R. N. (2024) · Veterinary Pathology · doi:10.1177/03009858241273318 · Cited by 7
“15 In addition, SOX-10 has shown to be comparable or superior to S-100 in the identification of metastatic and micrometastatic melanoma in lymph nodes in humans.”
Rekhi, B. (2020) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_832_19 · Cited by 7
Sox10 positive breast carcinoma metastatic to the skin
Slater, N. A., & Googe, P. B. (2018) · Journal of Cutaneous Pathology · doi:10.1111/cup.13114 · Cited by 6
Transcriptional profile and chromatin accessibility in zebrafish melanocytes and melanoma tumors
Kramer, E. T., Godoy, P. M., & Kaufman, C. K. (2021) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkab379 · Cited by 6
Non-mesenchymal Mimics of Sarcoma
Doyle, L. A. (2015) · Surgical pathology clinics · doi:10.1016/j.path.2015.05.010 · Cited by 5
Rate of Immunohistochemistry Utilization in the Diagnosis of Cutaneous Melanocytic Lesions
Chen, T. C., & Hitchcock, M. G. (2021) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001946 · Cited by 5
TRPS1 expression in breast angiosarcoma
Pancsa, T., Pósfai, B., Schubert, A., Almási, S., Papp, E., Chien, Y.-C. C., Kálmán, E., Kovács, K. A., Kulka, J., Varga, L., et al. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03852-2 · Cited by 4
“Similarly, SOX10 staining is characteristic of melanocytic tumors and soft tissue neoplasms with neural crest origin [31, 32].”
Therapeutic Opportunities in Melanoma Through PRAME Expression
Mokos, M., Prkačin, I., Gaćina, K., Brkić, A., Pondeljak, N., & Šitum, M. (2025) · Biomedicines · doi:10.3390/biomedicines13081988 · Cited by 4
“S100 and SOX10 are highly sensitive for melanocytic differentiation but lack specificity, as they stain both benign and malignant melanocytes [4,68,69].”
Optical feedback effects on terahertz quantum cascade lasers: modelling and applications
Rakić, A. D., Lim, Y. L., Taimre, T., Agnew, G., Qi, X., Bertling, K., Han, S., Wilson, S. J., Kundu, I., Grier, A., et al. (2016) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2250621 · Cited by 4
Diagnosis of Stage IV Melanoma
Tarhini, A. A., Agarwala, S. S., Khunger, A., Wahl, R. L., & Balch, C. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_29 · Cited by 4
Tchernev, G., Kandathil, L. J., Oliveira, N., Cardoso, J. C., & Patterson, J. W. (2022) · Dermatology Reports · doi:10.4081/dr.2022.9505 · Cited by 4
Siarov, J., Kumar, D., Paoli, J., Mölne, J., Gillstedt, M., & Neittaanmäki, N. (2024) · Diagnostic Pathology · doi:10.1186/s13000-024-01532-y · Cited by 4
“We chose to employ the SOX10 immunostain because it’s the reference standard at our department, showing nearly 100% sensitivity in detection of melanocytes in the epidermis [19].”
Method
Metadata
- Authors
- Mohamed, A., Gonzalez, R. S., Lawson, D., Wang, J., & Cohen, C.
- Affiliations
- Emory University (US)
- Venue
- Applied Immunohistochemistry & Molecular Morphology
- Published
- 2013-12
- Volume
- 21
- Issue
- 6
- Pages
- 506-510
- ISSN
- 1533-4058 (ISSN-L)
- 1541-2016
- OpenAlex
- W2037033919
- Cited by
- 159
- References
- 8
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 12 · 2023: 12 · 2022: 20 · 2021: 9 · 2020: 16 · 2019: 12 · 2018: 13 · 2017: 7 · 2016: 15 · 2015: 11 · 2014: 12 · 2013: 3
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Applied immunohistochemistry & molecular morphology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Keywords
- SOX10, melanoma, desmoplastic melanoma, spindle cell melanoma, epithelioid melanoma, melanocyte differentiation, benign nevi, dysplastic nevi, breast cancer, sensitivity and specificity, metastatic melanoma, ovarian carcinoma, endometrial cancer, lung cancer, colon cancer
- MeSH terms
- Cutaneous Malignant Melanoma, Melanoma, Cutaneous Malignant, Breast Neoplasms, Carcinoma, Colonic Neoplasms, Female, Humans, Immunohistochemistry, Lung Neoplasms, Male, Melanoma, Nevus, Ovarian Neoplasms, Sensitivity and Specificity, Skin Neoplasms, Biomarkers, Tumor, Gene Expression, Case-Control Studies, Endometrial Neoplasms, SOXE Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.